A phase III study of STI-001 a biosimilar/biobetter antibody for Cetuximab in combination of irinotecan or irinotecan alone for the treatment of metastatic colorectal carcinoma

Trial Profile

A phase III study of STI-001 a biosimilar/biobetter antibody for Cetuximab in combination of irinotecan or irinotecan alone for the treatment of metastatic colorectal carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2016

At a glance

  • Drugs Cetuximab biobetter (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2016 New trial record
    • 11 Jan 2016 According to a Sorrento Therapeutics media release, the primary end points (Overall Response Rate, Progressfree Survival, Overall Survival) were met.
    • 11 Jan 2016 According to a Sorrento Therapeutics media release, the company announced positive data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top